HK1214947A1 - 抗體製劑 - Google Patents

抗體製劑

Info

Publication number
HK1214947A1
HK1214947A1 HK16102906.1A HK16102906A HK1214947A1 HK 1214947 A1 HK1214947 A1 HK 1214947A1 HK 16102906 A HK16102906 A HK 16102906A HK 1214947 A1 HK1214947 A1 HK 1214947A1
Authority
HK
Hong Kong
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
HK16102906.1A
Other languages
English (en)
Inventor
Michael Adler
Hanns-Christian Mahler
Christine Wurth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40532665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1214947(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1214947A1 publication Critical patent/HK1214947A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
HK16102906.1A 2007-12-21 2016-03-14 抗體製劑 HK1214947A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07150335 2007-12-21

Publications (1)

Publication Number Publication Date
HK1214947A1 true HK1214947A1 (zh) 2016-08-12

Family

ID=40532665

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102906.1A HK1214947A1 (zh) 2007-12-21 2016-03-14 抗體製劑

Country Status (33)

Country Link
US (2) US20090162352A1 (zh)
EP (1) EP2234600B1 (zh)
JP (1) JP5881950B2 (zh)
KR (1) KR101247418B1 (zh)
CN (2) CN101896163A (zh)
AR (1) AR069788A1 (zh)
AU (1) AU2008340429C1 (zh)
BR (1) BRPI0820819B1 (zh)
CA (1) CA2708869C (zh)
CL (1) CL2008003788A1 (zh)
CO (1) CO6280464A2 (zh)
CR (1) CR11461A (zh)
CY (1) CY1115932T1 (zh)
DK (1) DK2234600T3 (zh)
EC (1) ECSP10010295A (zh)
ES (1) ES2511844T3 (zh)
HK (1) HK1214947A1 (zh)
HR (1) HRP20141249T1 (zh)
IL (1) IL206103A (zh)
MA (1) MA31984B1 (zh)
MX (1) MX2010006395A (zh)
MY (1) MY171841A (zh)
NZ (1) NZ585516A (zh)
PE (1) PE20091328A1 (zh)
PL (1) PL2234600T3 (zh)
PT (1) PT2234600E (zh)
RS (1) RS53551B1 (zh)
RU (1) RU2476238C2 (zh)
SI (1) SI2234600T1 (zh)
TW (1) TWI404728B (zh)
UA (1) UA101487C2 (zh)
WO (1) WO2009080541A1 (zh)
ZA (1) ZA201003907B (zh)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004033499A1 (ja) * 2002-10-11 2006-02-09 中外製薬株式会社 細胞死誘導剤
PL1692182T3 (pl) 2003-11-05 2010-09-30 Roche Glycart Ag Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
EP1710255A4 (en) * 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
JP4799405B2 (ja) * 2004-04-09 2011-10-26 中外製薬株式会社 細胞死誘導剤
TW200722518A (en) * 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
US9241994B2 (en) * 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
EP3348639A3 (en) * 2005-06-10 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Sc(fv)2 site-directed mutant
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP2048230A4 (en) * 2006-07-13 2010-01-20 Chugai Pharmaceutical Co Ltd ZELLTODINDUZIERER
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
AU2013266987B2 (en) * 2009-09-11 2016-11-10 F. Hoffmann-La Roche Ag Highly concentrated pharmaceutical formulations comprising anti - CD20 antibody
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR20120110175A (ko) * 2009-12-29 2012-10-09 에프. 호프만-라 로슈 아게 항체 제제
SI3345615T1 (sl) 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)
FR2962908A1 (fr) 2010-07-20 2012-01-27 Lfb Biotechnologies Formulation d'anticorps anti-cd20
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
WO2013063516A1 (en) 2011-10-28 2013-05-02 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
IN2014DN07149A (zh) 2012-01-27 2015-04-24 Neotope Biosciences Ltd
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
CN103059258A (zh) * 2012-12-07 2013-04-24 青岛文创科技有限公司 一种有机硅改性水性聚氨酯乳液
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN103012731A (zh) * 2012-12-17 2013-04-03 青岛森淼实业有限公司 一种水性聚氨酯抗起球剂的制备方法
SG11201507475UA (en) * 2013-03-13 2015-10-29 Genentech Inc Antibody formulations
US11433029B2 (en) 2013-03-15 2022-09-06 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
KR20160131073A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg4-5에 대해 특이적인 항-라미닌4 항체
KR20160127825A (ko) 2014-03-12 2016-11-04 프로테나 바이오사이언시즈 리미티드 항-mcam 항체 및 관련된 사용 방법
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
ES2949173T3 (es) 2014-09-15 2023-09-26 Hoffmann La Roche Formulaciones de anticuerpo
CN105708811A (zh) * 2014-12-01 2016-06-29 西藏海思科药业集团股份有限公司 一种稳定的重组人抗cd20单克隆抗体的冻干制剂
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2018096445A1 (en) * 2016-11-22 2018-05-31 Biocon Limited Stable formulation of recombinant humanized monoclonal antibody
CN108261544B (zh) * 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261391B (zh) * 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112020007731A2 (pt) * 2017-10-19 2020-10-20 F. Hoffmann-La Roche Ag composição farmacêutica para o tratamento de linfoma de células b, uso do obinutuzumabe e método para tratar o linfoma de células b cd20-positivo
SG11202009876TA (en) * 2018-04-10 2020-11-27 Dr Reddy’s Laboratories Ltd Stable formulations of therapeutic antibody
WO2020055360A2 (en) * 2018-08-10 2020-03-19 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi The parenteral composition comprising carfilzomib
EA202191201A1 (ru) * 2018-12-03 2022-01-26 Эдженсис, Инк. Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения
CN112675126A (zh) * 2019-10-18 2021-04-20 百奥泰生物制药股份有限公司 抗cd20抗体制剂及其应用
JP2023507053A (ja) * 2019-10-12 2023-02-21 バイオ－セラ ソリューションズ リミテッド 抗ｃｄ２０抗体製剤及びｃｄ２０陽性疾患の治療のための抗ｃｄ２０抗体の使用
CN113081955B (zh) * 2020-01-09 2023-10-24 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的制剂
CN112578117B (zh) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用
CN113855798A (zh) * 2021-09-30 2021-12-31 佛山汉腾生物科技有限公司 抗cd20的抗体制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
DK0999853T3 (da) * 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2003032913A2 (en) * 2001-10-16 2003-04-24 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
BRPI0411276A (pt) * 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
PL1692182T3 (pl) * 2003-11-05 2010-09-30 Roche Glycart Ag Przeciwciała CD20 o zwiększonym powinowactwie wiązania z receptorem Fc oraz zwiększonej funkcji efektorowej
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
PE20100748A1 (es) * 2005-12-12 2010-11-12 Hoffmann La Roche Anticuerpo anti beta-4-amiloide que contiene asparagina glicosilada en la region variable de vh
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
JP2009531371A (ja) * 2006-03-28 2009-09-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤

Also Published As

Publication number Publication date
TW200934792A (en) 2009-08-16
PE20091328A1 (es) 2009-09-03
RS53551B1 (en) 2015-02-27
US20090162352A1 (en) 2009-06-25
ZA201003907B (en) 2011-03-30
ECSP10010295A (es) 2010-07-30
RU2476238C2 (ru) 2013-02-27
EP2234600A1 (en) 2010-10-06
CA2708869C (en) 2016-06-28
CR11461A (es) 2010-08-16
IL206103A (en) 2016-07-31
UA101487C2 (en) 2013-04-10
KR101247418B1 (ko) 2013-03-25
HRP20141249T1 (en) 2015-03-13
BRPI0820819B1 (pt) 2021-06-08
KR20100087038A (ko) 2010-08-02
CN101896163A (zh) 2010-11-24
CN105126099A (zh) 2015-12-09
PL2234600T3 (pl) 2015-02-27
JP5881950B2 (ja) 2016-03-09
WO2009080541A1 (en) 2009-07-02
NZ585516A (en) 2012-07-27
CL2008003788A1 (es) 2010-02-19
AU2008340429C1 (en) 2016-09-08
US20150353640A1 (en) 2015-12-10
PT2234600E (pt) 2014-09-25
BRPI0820819A2 (pt) 2015-06-16
TWI404728B (zh) 2013-08-11
JP2011506538A (ja) 2011-03-03
ES2511844T3 (es) 2014-10-23
RU2010129481A (ru) 2012-01-27
IL206103A0 (en) 2010-11-30
CA2708869A1 (en) 2009-07-02
AU2008340429A1 (en) 2009-07-02
DK2234600T3 (da) 2014-09-08
MA31984B1 (fr) 2011-01-03
CO6280464A2 (es) 2011-05-20
MY171841A (en) 2019-11-04
MX2010006395A (es) 2010-07-01
AU2008340429B2 (en) 2015-02-12
SI2234600T1 (sl) 2014-12-31
AR069788A1 (es) 2010-02-17
CY1115932T1 (el) 2017-01-25
EP2234600B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
IL276622A (en) Antibody formulation
HK1214947A1 (zh) 抗體製劑
EP2077859A4 (en) ANTIBODY FORMULATION
EP2358392A4 (en) ANTIBODY FORMULATION
IL193408A0 (en) Antibody formulation
HK1207652A1 (zh) 抗體製劑
IL202648A0 (en) Antibody formulations
EP2173163A4 (en) ANTIBODY FORMULATIONS
HK1136970A1 (zh) 五特異性抗體
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
ZA201101343B (en) Novel antibody formulation
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
IL205073A0 (en) Anti-bst2 antibody
GB0707463D0 (en) Formulation
GB0712972D0 (en) Formulation
EP2167635A4 (en) ANTIBODY FORMULATIONS
EP2142200A4 (en) HOMOEOPATHIC FORMULA
GB0723044D0 (en) Lyophillised antigen composition
GB0723900D0 (en) Lyophillised antigen composition